Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
Where should businesses draw the line with large language model utilization?
Advertising big wigs say they may flee Meta platforms if their brands appear next to toxic content. But where else would they go?
Some 8,000 industry movers and shakers are expected today for the annual JPMorgan Healthcare Conference, or simply JPM.